[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:angelman-syndrome":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":80,"states":85},"Angelman Syndrome",11,7,[8,16,23,29,36,42,48,54,61,67,74],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05127226","HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-03T01:55:52.940420Z","2026-05-05T02:43:28.177807Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07157254","A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)",[20],"Phase 2","2026-08-26T02:15:39.267524Z","2026-05-05T02:43:28.075802Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07181837","A Phase 1\u002F2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome",[12],"2026-08-26T02:18:26.932189Z","2026-04-29T02:57:57.156357Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT06914609","REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome",[33],"Phase 3","2026-08-26T02:17:59.904383Z","2026-04-29T02:57:57.142273Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT07605429","BEACON - Phase III Clinical Study of Rugonersen in Angelman Syndrome.",[33],"2026-08-26T02:18:51.009190Z","2026-07-30T01:46:14.445861Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT07417137","A Natural History Study of Angelman Syndrome",[],"2026-08-26T02:19:23.493898Z","2026-05-13T02:55:06.701341Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT04507997","Angelman Syndrome Natural History Study",[],"2026-08-26T02:16:49.565137Z","2026-05-13T02:55:06.252149Z",{"nct_id":55,"title":56,"phases":57,"status":58,"updated_at":59,"content_modified":60},"NCT06415344","Long-term Extension of GTX-102 in Angelman Syndrome",[33],"ENROLLING_BY_INVITATION","2026-08-26T02:16:38.053590Z","2026-07-30T01:46:14.462467Z",{"nct_id":62,"title":63,"phases":64,"status":58,"updated_at":65,"content_modified":66},"NCT03836300","Parent and Infant Inter(X)Action Intervention (PIXI)",[],"2026-08-26T02:18:48.678868Z","2026-06-16T05:54:07.971455Z",{"nct_id":68,"title":69,"phases":70,"status":71,"updated_at":72,"content_modified":73},"NCT06139172","Web Intervention for Parents of Youth With Genetic Syndromes (WINGS)",[],"ACTIVE_NOT_RECRUITING","2026-08-03T02:17:43.428438Z","2026-05-05T02:43:28.714182Z",{"nct_id":75,"title":76,"phases":77,"status":71,"updated_at":78,"content_modified":79},"NCT03655223","Early Check: Expanded Screening in Newborns",[],"2026-08-03T03:53:57.297126Z","2026-06-16T05:54:07.977837Z",[81],{"biomarker":82,"count":83,"slug":84},"Ubiquitin-Protein Ligase E3A",6,"ubiquitin-protein-ligase-e3a",[86,89,92,95,98,102,105],{"state":87,"count":6,"slug":88},"California","california",{"state":90,"count":6,"slug":91},"Illinois","illinois",{"state":93,"count":6,"slug":94},"North Carolina","north-carolina",{"state":96,"count":83,"slug":97},"Massachusetts","massachusetts",{"state":99,"count":100,"slug":101},"Colorado",3,"colorado",{"state":103,"count":100,"slug":104},"Georgia","georgia",{"state":106,"count":100,"slug":107},"Texas","texas"]